MetaCap

Rein Therapeutics (RNTX) vs Serina Therapeutics (SER)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Serina Therapeutics (SER) has outperformed Rein Therapeutics (RNTX) over the past year, losing 71.9% versus a loss of 77.2%. Over five years, SER leads with a -95.6% price change compared with -97.5% for RNTX. Serina Therapeutics is the larger company by market cap ($29.8 million vs $29.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RNTX-77.24%SER-71.93%
+32%-25%-82%
Nov 21, 20251 yearNov 20, 2026
RNTX-97.57%SER-96.03%
+46%-29%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RNTX versus SER key metrics
MetricRNTXSER
Share price$0.3369$1.12
Market cap$29.06M$29.76M
1-day change-8.38%-6.67%
YTD return-70.96%-41.45%
1-year return-77.24%-71.93%
5-year return-97.47%-95.64%
EPS (TTM)$-1.51$-1.63
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$130.00K
Revenue growth (YoY)—+132.14%
Net income (latest FY)$-49.87M$-19.18M
Operating margin—-18478.46%
Net margin—-14755.38%
52-week high$2.10$4.26
52-week low$0.284$1.06
Distance from 52-week high-83.96%-73.71%
Analyst consensusnonenone
Avg. price target upside+1680.94%+748.21%
Average volume586.68K68.98K
Shares outstanding86.27M26.57M
Employees1016
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Rein Therapeutics

RNTX stock →

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

About Serina Therapeutics

SER stock →

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

RNTX vs SER FAQ

Which is bigger, Rein Therapeutics or Serina Therapeutics?

Serina Therapeutics (SER) is larger, with a market capitalization of $29.76M compared with $29.06M for Rein Therapeutics (RNTX).

Which stock has performed better over the past year, RNTX or SER?

SER returned -71.93% over the past 12 months, compared with -77.24% for RNTX (price return, excluding dividends). Past performance does not predict future results.

Are Rein Therapeutics and Serina Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons